GB201616699D0 - Antibodies - Google Patents

Antibodies

Info

Publication number
GB201616699D0
GB201616699D0 GBGB1616699.3A GB201616699A GB201616699D0 GB 201616699 D0 GB201616699 D0 GB 201616699D0 GB 201616699 A GB201616699 A GB 201616699A GB 201616699 D0 GB201616699 D0 GB 201616699D0
Authority
GB
United Kingdom
Prior art keywords
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1616699.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MAB DESIGNS Ltd
Original Assignee
MAB DESIGNS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MAB DESIGNS Ltd filed Critical MAB DESIGNS Ltd
Priority to GBGB1616699.3A priority Critical patent/GB201616699D0/en
Publication of GB201616699D0 publication Critical patent/GB201616699D0/en
Priority to PCT/EP2017/074872 priority patent/WO2018060480A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB1616699.3A 2016-09-30 2016-09-30 Antibodies Ceased GB201616699D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1616699.3A GB201616699D0 (en) 2016-09-30 2016-09-30 Antibodies
PCT/EP2017/074872 WO2018060480A1 (en) 2016-09-30 2017-09-29 Anti-mesothelin antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1616699.3A GB201616699D0 (en) 2016-09-30 2016-09-30 Antibodies

Publications (1)

Publication Number Publication Date
GB201616699D0 true GB201616699D0 (en) 2016-11-16

Family

ID=57571035

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1616699.3A Ceased GB201616699D0 (en) 2016-09-30 2016-09-30 Antibodies

Country Status (2)

Country Link
GB (1) GB201616699D0 (en)
WO (1) WO2018060480A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
TW201930355A (en) 2017-12-19 2019-08-01 英商Ｆ星貝塔有限公司 Binding members
EP3801574A4 (en) * 2018-05-31 2022-03-16 Washington University Methods for genome editing and activation of cells
EP4132969A4 (en) * 2020-04-07 2024-05-01 Fred Hutchinson Cancer Center Anti-mesothelin antigen-binding molecules and uses thereof
WO2023115528A1 (en) * 2021-12-24 2023-06-29 Zhejiang Shimai Pharmaceutical Co., Ltd. Antibodies against mesothelin and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010457A1 (en) 1989-03-14 1990-09-20 New York University Method of treating hiv infections using immunotoxins
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
JP2000505787A (en) 1996-01-05 2000-05-16 アメリカ合衆国 Mesothelial antigen and method and kit for targeting it
US6809184B1 (en) 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
EP2011801A1 (en) 1999-05-27 2009-01-07 Government of the United States as represented by the Secretary, Department of Health and Human Services Immunoconjugates having high binding affinity
US9090709B2 (en) * 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
WO2014004549A2 (en) * 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
GB201213858D0 (en) 2012-08-03 2012-09-19 Mab Design Ltd Method

Also Published As

Publication number Publication date
WO2018060480A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
ZA201900373B (en) Anti-tim-3 antibodies
HK1253507A1 (en) Anti-ror1 antibodies
HK1256116A1 (en) Anti-lag-3 antibodies
SG10201601719RA (en) Anti-LAG-3 Antibodies
GB201601073D0 (en) Antibodies
GB201621439D0 (en) IL-11Ra Antibodies
GB201521391D0 (en) Antibodies
GB201521393D0 (en) Antibodies
HK1246804A1 (en) Tau-binding antibodies
GB201521382D0 (en) Antibodies
IL253633A0 (en) Anti-transthyretin antibodies
HK1255056A1 (en) Anti-cd115 antibodies
SG11201706125QA (en) Anti-transthyretin antibodies
HUE059592T2 (en) Anti-transthyretin antibodies
GB201610044D0 (en) Antibodies
GB201508180D0 (en) Antibodies
GB201603291D0 (en) Antibodies
IL264262A (en) Anti-il-22r antibodies
GB201616699D0 (en) Antibodies
GB201509907D0 (en) Antibodies
ZA201808317B (en) Anti-tnfrsf25 antibodies
IL260083B1 (en) Anti-myl9 antibody
GB201522394D0 (en) Antibodies
GB201503438D0 (en) Antibodies
GB201622197D0 (en) Antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)